Additional Relevant Details - Potential Treatment for Patients with Facial Erythema (Redness) Associated with Rosacea -
- Allergan Expects PDUFA Date in First Half 2017 -

Allergan announced that the New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults, has been accepted by the U.S. Food and Drug Administration (FDA) for standard review. Allergan expects the Prescription Drug User Fee Act (PDUFA) date to be in the first half of 2017.